Abstract
Alterations in tyrosine kinase expression or functionality have been linked to tumor growth, and detailed analysis of tyrosine kinase pathways has led to the development of novel anticancer drugs based on their inhibition. The aim of the present work was to examine the cytotoxicity and cellular alterations correlated with multidrug resistance mechanisms induced by three tyrosine kinase inhibitors, lapatinib, sorafenib and gefitinib. The study was performed on three breast cancer cell lines (BRC-230, MCF-7 and SkBr3). Drug-induced growth inhibition was detected by Sulforhodamine B analysis. Apoptosis, cytosolic calcium alteration, extrusion pump activity and mitochondrial membrane depolarization were assessed by flow cytometry. Drug efflux-related gene expression was analyzed by RT-PCR and drug target protein expression was evaluated by Western Blot. Lapatinib and gefitinib induced a cytotoxic effect and mitochondrial membrane depolarization in BRC-230 and SkBr3 cells, while sorafenib induced apoptosis and a high and rapid dissipation of mitochondrial potential in all cell lines. Moreover, all three drugs produced a rapid cytosolic calcium mobilization from endoplasmic reticulum stores in the investigated cell lines and a strong decrease in multidrug transporter activity in BRC- 230 and MCF-7 cells. Mitochondrial membrane depolarization and inhibition of multidrug transporter activity induced by tyrosine kinase inhibitors were independent of cytosolic calcium mobilization. These data suggest that the investigated drugs possess mechanisms of action that are independent of drug target expression, opening up further possibilities for the development of new therapeutic strategies.
Keywords: Tyrosine kinase inhibitor, breast cancer, in vitro study, calcium, multidrug resistance, mitochondrial depolarization, ABC transporters
Current Cancer Drug Targets
Title: Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells
Volume: 10 Issue: 4
Author(s): S. Carloni, F. Fabbri, G. Brigliadori, P. Ulivi, R. Silvestrini, D. Amadori and W. Zoli
Affiliation:
Keywords: Tyrosine kinase inhibitor, breast cancer, in vitro study, calcium, multidrug resistance, mitochondrial depolarization, ABC transporters
Abstract: Alterations in tyrosine kinase expression or functionality have been linked to tumor growth, and detailed analysis of tyrosine kinase pathways has led to the development of novel anticancer drugs based on their inhibition. The aim of the present work was to examine the cytotoxicity and cellular alterations correlated with multidrug resistance mechanisms induced by three tyrosine kinase inhibitors, lapatinib, sorafenib and gefitinib. The study was performed on three breast cancer cell lines (BRC-230, MCF-7 and SkBr3). Drug-induced growth inhibition was detected by Sulforhodamine B analysis. Apoptosis, cytosolic calcium alteration, extrusion pump activity and mitochondrial membrane depolarization were assessed by flow cytometry. Drug efflux-related gene expression was analyzed by RT-PCR and drug target protein expression was evaluated by Western Blot. Lapatinib and gefitinib induced a cytotoxic effect and mitochondrial membrane depolarization in BRC-230 and SkBr3 cells, while sorafenib induced apoptosis and a high and rapid dissipation of mitochondrial potential in all cell lines. Moreover, all three drugs produced a rapid cytosolic calcium mobilization from endoplasmic reticulum stores in the investigated cell lines and a strong decrease in multidrug transporter activity in BRC- 230 and MCF-7 cells. Mitochondrial membrane depolarization and inhibition of multidrug transporter activity induced by tyrosine kinase inhibitors were independent of cytosolic calcium mobilization. These data suggest that the investigated drugs possess mechanisms of action that are independent of drug target expression, opening up further possibilities for the development of new therapeutic strategies.
Export Options
About this article
Cite this article as:
Carloni S., Fabbri F., Brigliadori G., Ulivi P., Silvestrini R., Amadori D. and Zoli W., Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells, Current Cancer Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/156800910791208580
DOI https://dx.doi.org/10.2174/156800910791208580 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives
Current Medicinal Chemistry Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Cytotoxic and Apoptogenic Activity of a Methanolic Extract from the Marine Invertebrate Ciona intestinalis on Malignant Cell Lines
Medicinal Chemistry Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis
Current Pharmaceutical Design Design and Application of Magnetic-Based Theranostic Nanoparticle Systems
Recent Patents on Biomedical Engineering (Discontinued) Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling in Cancer Development and Progression
Current Cancer Drug Targets Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The BCL2-Family of Protein Ligands as Cancer Drugs: The Next Generation of Therapeutics
Current Medicinal Chemistry - Anti-Cancer Agents The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution
Current Genomics Discovery of New Small Molecules and Targets Towards Angiogenesis Via Chemical Genomics Approach
Current Drug Targets Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets The Assessment of Platelet Activation in Antiplatelet Drug Development
Current Medicinal Chemistry Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets Combination Therapy for the Treatment of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer
Current Cancer Drug Targets